“We continue progressing with the strategic repositioning toward becoming a leading provider of innovative RNA delivery technology,” commented Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO. “We have achieved great strides in enhancing awareness and visibility of our OligoPhore(TM) / SemaPhore(TM) platforms for extrahepatic RNA delivery and efficient endosomal release; as a result, we recently entered into our first collaboration with a biopharmaceutical company. We look forward to working with Heqet Therapeutics, in the framework of this first collaboration, on their mission to develop treatments for cardiac regeneration, applying RNA with our OligoPhore(TM) platform. We are excited to see interest in our technology growing steadily and remain confident about the potential to develop further partnerships with biopharmaceutical companies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTO:
- Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
- Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
- Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
- Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
- Altamira Therapeutics, Pharma Nordic enter exclusive agreement for Bentrio
